Abivax (NASDAQ:ABVX) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Abivax (NASDAQ:ABVX) in a research note published on Monday morning, MarketBeat reports. The firm issued a buy rating and a $160.00 price target on the stock.

Other analysts have also issued research reports about the company. Guggenheim reissued a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Thursday, December 18th. Oppenheimer set a $131.00 target price on Abivax in a research note on Thursday, January 8th. Truist Financial set a $140.00 target price on Abivax in a research report on Monday, November 24th. Piper Sandler reiterated an “overweight” rating and set a $142.00 price target on shares of Abivax in a research note on Tuesday, December 16th. Finally, Wedbush started coverage on shares of Abivax in a report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Abivax presently has an average rating of “Moderate Buy” and an average price target of $136.69.

Abivax Stock Down 2.1%

NASDAQ ABVX opened at $123.99 on Monday. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83. The stock has a market cap of $9.80 billion, a PE ratio of -29.66 and a beta of 1.00. The firm has a 50-day simple moving average of $119.08 and a 200 day simple moving average of $109.81. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The company had revenue of ($4.92) million during the quarter. On average, research analysts forecast that Abivax will post -2.83 EPS for the current year.

Hedge Funds Weigh In On Abivax

Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp bought a new stake in Abivax during the 3rd quarter worth about $36,000. Bank of America Corp DE increased its position in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in Abivax in the 3rd quarter valued at about $52,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after acquiring an additional 344 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.